168 related articles for article (PubMed ID: 23990986)
1. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
2. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
3. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
4. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
[TBL] [Abstract][Full Text] [Related]
5. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
[TBL] [Abstract][Full Text] [Related]
6. PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
[TBL] [Abstract][Full Text] [Related]
7. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.
Johansson I; Aaltonen KE; Ebbesson A; Grabau D; Wigerup C; Hedenfalk I; Rydén L
Genes Chromosomes Cancer; 2012 Apr; 51(4):375-83. PubMed ID: 22170730
[TBL] [Abstract][Full Text] [Related]
8. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
9. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
[TBL] [Abstract][Full Text] [Related]
10. Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
Ramos AH; Dutt A; Mermel C; Perner S; Cho J; Lafargue CJ; Johnson LA; Stiedl AC; Tanaka KE; Bass AJ; Barretina J; Weir BA; Beroukhim R; Thomas RK; Minna JD; Chirieac LR; Lindeman NI; Giordano T; Beer DG; Wagner P; Wistuba II; Rubin MA; Meyerson M
Cancer Biol Ther; 2009 Nov; 8(21):2042-50. PubMed ID: 19755855
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
[TBL] [Abstract][Full Text] [Related]
13. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
[TBL] [Abstract][Full Text] [Related]
14. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.
Blom T; Roselli A; Häyry V; Tynninen O; Wartiovaara K; Korja M; Nordfors K; Haapasalo H; Nupponen NN
J Neurooncol; 2010 Apr; 97(2):217-24. PubMed ID: 19779861
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.
Ruano Y; Mollejo M; Ribalta T; Fiaño C; Camacho FI; Gómez E; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
Mol Cancer; 2006 Sep; 5():39. PubMed ID: 17002787
[TBL] [Abstract][Full Text] [Related]
16. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.
Niini T; López-Guerrero JA; Ninomiya S; Guled M; Hattinger CM; Michelacci F; Böhling T; Llombart-Bosch A; Picci P; Serra M; Knuutila S
Genes Chromosomes Cancer; 2010 Feb; 49(2):132-43. PubMed ID: 19862822
[TBL] [Abstract][Full Text] [Related]
17. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
18. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
[TBL] [Abstract][Full Text] [Related]
19. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
Zietsch J; Ziegenhagen N; Heppner FL; Reuss D; von Deimling A; Holtkamp N
PLoS One; 2010 Jul; 5(7):e11858. PubMed ID: 20686603
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
